Concepedia

Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial

Homa Taheri, Hossein Chiti, Tara Reshadmanesh, Sepehr Gohari, Ahmad Jalilvand, Shahram Arsang‐Jang, Faramarz Ismail‐Beigi, Samin Ghanbari, Mohsen Dadashi, Atieh Asgari,

Journal of Diabetes & Metabolic Disorders · 2023 · 13 citations · 26 references

DOIFull text

Open access

Concepts

References

26

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

, , +15

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

Robert Ćhilton, I. Tikkanen, Christopher P. Cannon et al. · Diabetes Obesity and Metabolism · 2015 · 510 citations · Full text

, , +17

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

Matthew M.Y. Lee, Katriona Brooksbank, Kirsty Wetherall et al. · Circulation · 2020 · 437 citations · Full text

, , +17

Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data

Andrew J. Vickers · BMC Medical Research Methodology · 2005 · 394 citations · Full text

, , +16

Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial

Christopher S. Kovács, V Seshiah, Ros Swallow et al. · Diabetes Obesity and Metabolism · 2013 · 383 citations

, , +17